CD274 and neoplasm: PD-L1 signaling plays a key role in the immunosuppressive tumor microenvironment (TME) and is considered a predictive biomarker of response for anti–PD-(L)1 therapies in TNBC, where an estimated 20% of tumors express PD-L1 (10–13).